Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients

5 Mar 2015

Abstract excerpt

The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis, are clonal hematopoietic stem cell disorders frequently associated with a somatic JAK2V617F mutation. he gain-of-function JAK2V617F...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25745188
DOI: 10.1182/blood-2014-12-618074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patientsPMID 25745188Read ↗

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Semantic proximity Read ↗

A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

Functional Consequences of Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.Semantic proximity Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations.Semantic proximity Read ↗

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.Semantic proximity Read ↗

Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.Semantic proximity Read ↗

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.